Biotec Pharmacon ASA Issued New Patent for Cancer Adjuvant Therapy

Biotec Pharmacon ASA (OSX: BIOTEC) announces today that the United States Patent Office has issued a patent that covers the inventive treatment of several types of cancer using a combination of a large variety of monoclonal antibodies and beta-glucan. This new patent covers a novel treatment using a combination of monoclonal antibodies and yeast beta-glucan for treatment of cancer.

Biotec Pharmacon has developed this concept together with Memorial Sloan-Kettering Cancer Center (MSKCC) and enjoys an exclusive license on MSKCC’s rights to this patent.

The patent US 8,791,252 is for a method of treating a variety of different cancers by administrating a combination of a (1,3) beta-glucan and a complement-activating antibody.

"The co-operation with MSKCC in the area of adjuvant cancer therapy is moving forward, and this latest patent covers broad claims which will be important to develop new opportunities in this promising business area. The new US patent adds to several other patents and pending patent applications in many countries, and further solidifies our strong position within cancer antibody treatment using beta-glucans" says Svein Lien, CEO, Biotec Pharmacon ASA.

For further information:

CEO Svein W. F. Lien: +47 92289323

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. Biotec BetaGlucans develops and manufactures novel immunomodulating products, and has recently obtained CE-mark for Woulgan® Biogel containing its proprietary substance SBG®. Woulgan®

Biogel is a single-patient primary dressing for use on skin wounds, including diabetic ulcers, bedsores, leg ulcers, transplantation wounds, post-surgery wounds, trauma wounds, first- and second-degree burns, abrasions, and cuts. The company is currently performing a market evaluation study in collaboration with world leaders Smith & Nephew.

ArcticZymes develops, produces and sells enzymes of marine origin used in molecular DNA technologies and diagnostics, growth markets where rapid technological developments are creating a strong demand for new and improved enzymes.